Published in JAMA on November 14, 2012
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer (2016) 1.70
Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol (2014) 0.79
Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. Chin J Cancer (2016) 0.78
Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One (2015) 0.75
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 2.79
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 2.66
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol (2010) 2.38
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology (2002) 2.34
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology (2004) 2.09
Noninvasive monitoring of patients with chronic hepatitis C. Hepatology (2002) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology (2008) 1.95
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology (2002) 1.88
Re-weighting the model for end-stage liver disease score components. Gastroenterology (2008) 1.83
Clinical significance of hepatitis B virus genotypes. Hepatology (2002) 1.82
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology (2006) 1.76
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl (2007) 1.64
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Indications for therapy in hepatitis B. Hepatology (2009) 1.57
When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med (2007) 1.48
Chronic disease management for patients with cirrhosis. Gastroenterology (2010) 1.47
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol (2003) 1.45
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol (2003) 1.43
Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med (2009) 1.42
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Newer markers for hepatocellular carcinoma. Gastroenterology (2004) 1.31
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol (2006) 1.25
Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology (2012) 1.25
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl (2007) 1.10
A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol (2009) 1.06
Patient decision making about organ quality in liver transplantation. Liver Transpl (2011) 1.04
Management of hepatitis B patients with antiviral resistance. Antivir Ther (2004) 1.02
Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int (2009) 1.01
Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology (2012) 1.00
Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology (2011) 1.00
Viral factors and outcomes of chronic HBV infection. Am J Gastroenterol (2011) 0.98
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol (2010) 0.95
Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics (2002) 0.95
Update on viral hepatitis: 2008. Curr Opin Gastroenterol (2009) 0.93
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol (2004) 0.92
Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol (2004) 0.91
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother (2006) 0.91
Treatment of hepatitis B. J Gastroenterol (2002) 0.90
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89
Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol (2004) 0.88
Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology (2012) 0.88
[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. Rom J Gastroenterol (2004) 0.88
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88
Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc (2007) 0.87
HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. J Hepatol (2013) 0.87
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol (2004) 0.87
Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology (2006) 0.86
Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology (2004) 0.85
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int (2010) 0.83
The dawn of a new era: transforming our domestic response to hepatitis B & C. Gastroenterology (2010) 0.81
Is family history of liver cancer a risk factor for hepatocellular carcinoma? J Hepatol (2008) 0.81
Update on viral hepatitis: 2005. Curr Opin Gastroenterol (2006) 0.81
Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int (2006) 0.81
Combination of HBIG and lamivudine-resistant mutations: a formula for trouble? Liver Transpl (2002) 0.78
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78
Viral hepatitis at a crossroad. Gastroenterology (2012) 0.77
Treatment of hepatitis B: who, when, and how? Arch Intern Med (2006) 0.77
Update on viral hepatitis in 2004. Curr Opin Gastroenterol (2005) 0.77
Viral hepatitis in 2003. Curr Opin Gastroenterol (2004) 0.77
Natural history of hepatitis B and outcomes after liver transplantation. Clin Liver Dis (2003) 0.76
Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation. Med Decis Making (2008) 0.76
Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy? Liver Transpl (2005) 0.75
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl (2007) 0.75
Endpoints for clinical trials on treatment of hepatitis C. J Hepatol (2006) 0.75
Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. Am J Epidemiol (2017) 0.75
High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial. J Clin Gastroenterol (2002) 0.75
Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System. Eur J Gastroenterol Hepatol (2016) 0.75
New pharmacologic therapies in chronic hepatitis B. Gastroenterol Clin North Am (2010) 0.75